Oncogenic activation of the Ron tyrosine kinase (Macrophage Stimulating Protein receptor) relies on substitutions of two highly conserved residues in the catalytic domain (D1232V and M1254T), which result in ligand-independent activation of the receptor, in vivo tumorigenesis and metastasis. 
Oncogenic activation of the Ron tyrosine kinase (Macrophage Stimulating Protein receptor) relies on substitutions of two highly conserved residues in the catalytic domain (D1232V and M1254T), which result in ligand-independent activation of the receptor, in vivo tumorigenesis and metastasis. We show here that the Y/F conversion of the Y 1317 residue in the kinase domain impairs tumorigenic and metastatic properties of Ron activated by the MEN2B-like mutation (Ron M1254T ), but not by other two oncogenic substitutions. Furthermore, Ron M1254T lacking the multifunctional docking site retains transforming and metastatic activity. These data reveal that the transforming activity of Ron M1254T mutant is dependent on Y 1317 phosphorylation, suggesting a shift in intramolecular substrate speci®city. Consistently, a shift of Ron M1254T kinase substrate speci®city was observed by in vitro peptide phosphorylation assays and in vivo receptor autophosphorylation. The Y 1317 phosphorylation elicits by itself activation of PI-3K/Akt and MAPK signalling pathways. Our data indicate that the accomplishment of the full oncogenic phenotype of Ron M1254T requires the phosphorylation both of the canonical C-terminal docking site and of the unique Y 1317 residue in the tyrosine kinase domain. Oncogene (2000) 19, 5208 ± 5211.
Keywords: Ron; substrate speci®city; tumorigenesis; tyrosine phosphorylation Ron is the receptor for MSP (Macrophage Stimulating Protein; Gaudino et al., 1994; Wang et al., 1994) . Upon ligand stimulation, Ron signalling occurs through association to multiple eectors, as a consequence of the phosphorylation of a unique multifunctional docking site (Y   1353   VQLPATY   1360 MNL), conserved in the evolutionary related Met and Sea receptors (Ponzetto et al., 1994; Iwama et al., 1996; Wang et al., 1996) .
Receptor tyrosine kinases become oncogenic through a variety of mechanisms ± including overexpression, point mutations, partial deletions and gene rearrangements ± resulting in constitutive activation of the catalytic domain. Examples of activating mutations, directly aecting the structure of the TK domain are those found in the tyrosine kinases Kit, Met and Ret, associated to human mast cell leukaemia and human mastocytosis (Longley et al., 1996) , to HPRC (Human Papillary Renal Carcinoma; Schmidt et al., 1997) and to MEN2B (Multiple Endocrine Neoplasia type 2B; Carlson et al., 1994) . These consist of the substitution of a conserved aspartic acid residue in subdomain VII of the kinase with a neutral residue (in Kit and Met) and of a methionine residue in subdomain VIII of the kinase into threonine (in Met and Ret). Interestingly, these residues are highly conserved among the receptor tyrosine kinases, but have dierent identities in the cytosolic, non-receptor tyrosine kinases. Constitutive activation of a tyrosine kinase receptor can occur also by alteration of the sequence of the transmembrane domain. This is the case of p185 neu* , an oncogenic form of Neu, where a V?E substitution at position 664 induces constitutive dimerization, tyrosine kinase autophosphorylation and cell transformation (Weiner et al., 1989; Sternberg and Gullick, 1989) .
The Ron receptor acquires oncogenic potential by means of two single amino acid substitutions (Ron D1232V and Ron
M1254T
), targeted to the above mentioned conserved residues in the activation loop of the tyrosine kinase domain (Santoro et al., 1998; Williams et al., 1999) .
In the present investigation we addressed the molecular mechanisms responsible for cell transformation by oncogenic Ron, abrogating potentially alternative phosphorylation sites in dierent Ron oncogenic mutants. These were the previously described receptors carrying D1232V and M1254T substitutions respectively (Santoro et al., 1998) and the Ron Neu* chimaera, where the transmembrane domain is replaced by the corresponding sequence of oncogenic p185 neu* . A similar strategy has been used to generate a constitutive active and transforming PDGFb/Neu* receptor (Petti et al., 1998) .
Sequence analysis of the Ron intracellular region identi®ed, among several potential alternative substrates, the sequence LY 1317 QVM that: (i) contains a very conserved tyrosine residue among the members of the receptor tyrosine kinase family (Hanks and Quinn, 1991) , (ii) outlines a putative docking site for SH2-containing proteins (Songyang et al., 1993) , (iii) features a phosphorylation consensus for tyrosine kinases of the cytosolic type . This tyrosine was converted to phenylalanine in all mutationally activated Ron receptors (`single Wild-type and mutant cDNAs were tested for focus forming activity in NIH3T3 ®broblasts. As previously shown (Santoro et al., 1998) , wild-type Ron was totally ineective on cell transformation, whereas Ron D1232V and Ron M1254T were highly transforming. Interestingly, the Ron Neu* chimaera yielded the highest number of foci (957/10 mg transfected cDNA). The transforming properties of Ron D1232V and Ron Neu* were completely abolished by`double F' and`triple F' mutations. Surprisingly, the`double F' suppression mutant, when generated in Ron
, preserved the transforming ability of this receptor, although half-reduced. Conversely, the`single F' substitution of residue Y 1317 did not alter the focus forming activity of Ron Neu* and Ron
D1232V
, whereas in the case of Ron M1244T the number of foci was signi®cantly reduced, being 50% less. Interestingly,`triple F' mutations, suppressing both the multifunctional docking site and the Y 1317 site, totally abolished transforming ability of Ron , while a residual number of foci were induced by this mutant generated in Ron M1254T ( Figure 2 ). These data demonstrate that the M1254T substitution forces Ron M1254T to become partially independent from the phosphorylation of the canonical docking site.
We have previously demonstrated that NIH3T3 cells expressing Ron D1232V and Ron N1254T mutants mediate metastasis formation in nude mice (Santoro et al., 1998) . Similar results were obtained for Met (Jeers et Neu* the native transmembrane domain was replaced by that of the oncogenic rat neu (tm-neu * ). The Ron mutationally active Ron D1232V and Ron M1254T were generated by single point substitution in activation loop of the conserved residues D1232V and M1254T, respectively. The Y/F substitution of the critical tyrosine residues of the canonical multifunctional docking site (Y1353F and Y1360F) as well as of the putative alternative phosphorylation site (Y1317F) are indicated in underlined italic. The cDNA encoding for Ron, Ron D1232V and Ron M1254T have been previously described (Gaudino et al., 1994; Santoro et al., 1998) . The chimeric Ron Neu* receptor was generated by replacing the transmembrane (TM) domain of human Ron with that of rat p185 neu* , bearing the oncogenic Val/Glu 664 substitution. PCR mutagenesis was employed to generate a unique S®I site, used for deleting the fragment encoding the TM domain of Ron. Synthetic double-stranded oligonucleotides (sense 60 bp: 5'-TGTTCCTAATATTAGTG-GTGGT CGTTGGAATCCTAA TCCGGAGGAACAGCTAGT-TCTTC-3'; antisense 79 bp: 5'-ACCACTAATATTAGGAA-CAGCA GGACGCCCTCTACAGTTG CAATGA TGAATGTC-ACCGTGCTCTGGACCCCATCTG-3') were inserted into the S®I site, generating the Ron Neu* chimaera. All single (F), double (2F) and triple (3F) tyrosine/phenylalanine (Y/F) point mutations were introduced by site-directed mutagenesis, using the pAlterSites in vitro Mutagenesis System (Promega). Mutations were con®rmed by direct DNA cycle-sequencing (Amersham). (b) Expression and tyrosine phosphorylation of Ron mutants in NIH3T3 cells. All constructs were inserted in the pMT2 eukaryotic expression vector and co-transfected with pSVneo in NIH3T3 mouse embryo ®broblasts by the DNAcalcium phosphate procedure. The transfectants were selected in growth medium supplemented with 0.4 mg/ml of G418-sulphate. The panel shows Western analysis on anti-Ron immunoprecipitates from lysates of pooled NIH3T3 stable cell lines, expressing the indicated wild-type or mutated receptors, using anti-Ron antiserum (Gaudino et al., 1994) or anti-phosphotyrosine antibody (Upstate Biotechnology Inc.). Immunoprecipitation and Western blotting experiments were performed as previously described (Santoro et al., 1998) Figure 2 Oncogenic and metastatic properties of the Ron mutants. Transforming activity and in vivo experimental metastasis of NIH3T3 cells expressing the mutated Ron constructs. The focus forming assays were performed on NIH3T3 ®broblasts (5610 5 cells) that were co-transfected with 10 mg of each recombinant plasmid and 0.8 mg of pSV2-neo using the calcium phosphate precipitation technique (CellPhect, Pharmacia). Twenty-four hours after DNA transfection the cultures were split at low cell density into a 100 mm dishes, and incubated in DMEM medium supplemented with 5% foetal bovine serum. The cell cultures were maintained at con¯uence and screened for foci formation 15 ± 21 days later. All experiments were performed in triplicates and values represent the average (+s.d). Spontaneous formation of foci was negligible. To verify the transfection eciency, a fraction of cells were selected in G418-containing medium. Cells derived from foci were used only to test protein expression. To avoid clonal variability, in the Ron-mediated experimental lung colonization, 10 6 cells from pooled G418-selected NIH3T3 populations expressing each type of construct, were injected intravenously into the tail vein of athymic female nu/nu mice, as previously described (Santoro et al., 1998 , whereas suppression of multifunctional docking site in Ron M1254T maintained the ability to induce transformation and metastasis ( Figure  2) . The importance of Y 1317 is highlighted by the fact that all animals injected with cells expressing thè double F' mutant exhibited severe lung metastases, as in the case of non mutagenized Ron M1254T (data not shown). These results obtained in vivo reveal that the M1254T mutation completely subverts the canonical docking site required for Ron-induced lung tissue colonization.
It has been suggested that the M/T substitutions in the activation loop of Ret Santoro et al., 1995) , Kit (Piao et al., 1996) and Met (Bardelli et al., 1998) , can induce a subversion of substrate speci®city of the kinase. To investigate whether M1254T mutation could alter the Ron substrate ®delity, we performed in vitro phosphorylation assays on optimal peptide substrates for EGF receptor (EGFR) and for the Abl and Src cytosolic kinases, using Ron and Ron M1254T recombinant kinases expressed in insect cells. A marked alteration in substrate speci®city was observed for the Ron M1254T kinase, which phosphorylated eciently the peptides optimal substrate both for EGFR and for the cytosolic tyrosine kinase Abl. These results reveal that the M1254T substitution uniquely confers substrate speci®city of the cytosolic-type to the Ron kinase, in addition to its original unaltered speci®city for substrates of the receptor-type (Figure 3a) . Conversely, the other two oncogenic mutations did not aect Ron substrate speci®city (data not shown). This might explain why Ron M1254T phosphorylates both the tyrosine residues of the multifunctional docking site and Y 1317 residue, because the latter is embedded in a consensus sequence typical of cytosolic-type tyrosine kinases . Consistently, the level of in vivo tyrosine phosphorylation (receptor transautophosphorylation) was markedly reduced only in cells expressing Ron M1254T F, but not Ron M1254T 2F (Figure 1b) . This suggests for the Y 1317 residue the role of an alternative optimal tyrosine phosphorylation site for the kinases bearing the M1254T substitution.
It has been demonstrated that the Ron signalling to cell interior requires at least activation both of the PI3-kinase/Akt and of Ras/MAPK pathways (Li et al., 1995; Wang et al., 1996; Santoro et al., 1996) 2F) were totally inactive on these pathways (Figure 3b and data not shown). Moreover, Ron M1254T delivered a stronger signal that Ron Neu* and Ron
, possibly because of the synergy between the two phosphotyrosine motifs (Y 1317 (Y and YY 1353 (Y ,1360 ) occurring only in the receptor bearing the M1254T mutation. This assumption is strengthened by the fact that abrogation of Y 1317 in Ron M1254T F) reduces by half the levels of Akt M1254T intracellular domain were cloned in the Baculovirus Transfer Vector pBlueBacHis2 (Invitrogen) and expressed in recombinant form using Sf9 baculovirus cells. The insect cells were lysed 72 h after infection in lysis buer containing 1% Triton X-100, 2 mM sodium orthovanadate and inhibitors of proteases (aprotinin, 1 mg/ml; leupeptin, 500 mg/ml; phenilmethanelsulphonyl¯uoride, 1 mM). The cellular extracts were immunoprecipitated with Sepharose-protein A (AmershamPharmacia) and with Ron C-terminal antisera, and used to phosphorylate the optimal peptide substrates for epidermal growth factor receptor (EGFRs) AEEEEYFELVAKKKK (100 mM), Src (SRCs) AEEEIYGEFEAKKK (100 mM), Abl (ABLs) EAIYAAPFAKKK (100 mM) and Ron (RONs) RDIL-DREYYSVQQHR (100 mM). The reaction was performed in the kinase buer (25 mM HEPES, pH 7.5, 5 mM MnCl 2 , 2 mM DTT) in the presence of [g-32 P]ATP for 15 min at 48C (Songyang et al., 1994) . The amount of radioactivity incorporated was determined using the phosphocellulose assay (Pierce . Here the abrogation of the multifunctional docking site totally suppressed Ron signalling and consequently transformation and metastasis. Moreover, in these oncogenic Ron receptors, the expression of the Y/F 1317 substitution did not aect signalling and biological activity at all.
Recently, similar results were obtained for the mutationally activated Met receptor, bearing L1213V or M1268T substitutions, that overcomes the requirement for the phosphorylation of the multifunctional docking site. This suggests that the activating mutations stabilize an active conformation of the Met kinase, signalling through mechanisms distinct from those of wild-type Met (Jeers and Vande Woude, 1999) .
In conclusion, our results demonstrate that the Ron receptor carrying the M1254T mutation requires for the attainment of its full oncogenic program the phosphorylation of the unique Y 1317 residue as well as of the canonical C-terminal docking site. This is the ®rst demonstration by in vivo assays that the MEN2B-like amino acid substitution in¯uences the biological properties of a tyrosine kinase receptor, by altering its substrate speci®city.
It will be interesting to investigate whether a similar behaviour occurs in Ret and Met receptors, that are targets of the same M/T mutation in MEN2B and HPRC neoplasia, respectively.
